{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:32:58Z","timestamp":1778290378868,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":34,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ahjo.2022.100187","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T12:55:32Z","timestamp":1659704132000},"page":"100187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The evolution of \u201cpillars of therapy\u201d to reduce heart failure risk and slow diabetic kidney disease progression"],"prefix":"10.1016","volume":"19","author":[{"given":"Olivia","family":"Blazek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahjo.2022.100187_bb0005","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.2337\/dc22-S011","article-title":"11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahjo.2022.100187_bb0010","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ahjo.2022.100187_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194409","article-title":"Contemporary pillars of heart failure with reduced ejection fraction medical therapy","volume":"10","author":"Rahamim","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ahjo.2022.100187_bb0020","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/01.CIR.74.4.766","article-title":"Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system","volume":"74","author":"Packer","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2022.100187_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2578","article-title":"Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-reduced","author":"Zannad","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2022.100187_bb0030","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2022.100187_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","article-title":"SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob(-\/-) mice","volume":"18","author":"Adingupu","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0045","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/jcp.30621","article-title":"Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease","volume":"237","author":"Ravindran","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways","volume":"234","author":"Yaribeygi","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0055","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.ahjo.2022.100187_bb0060","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/j.ajkd.2019.05.009","article-title":"Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors","volume":"74","author":"Bakris","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ahjo.2022.100187_bb0065","doi-asserted-by":"crossref","first-page":"i48","DOI":"10.1093\/ndt\/gfz252","article-title":"Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?","volume":"35","author":"Neuen","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ahjo.2022.100187_bb0070","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0080","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0085","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000506275","article-title":"Finerenone reduces intrinsic arterial stiffness in Munich Wistar Fromter rats, a genetic model of chronic kidney disease","volume":"51","author":"Gil-Ortega","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0090","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","article-title":"Rationale and design of MinerAlocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2022.100187_bb0095","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2022.100187_bb0100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2022.100187_bb0105","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2022.100187_bb0110","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2022.100187_bb0115","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/ndt\/gfab336","article-title":"Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ahjo.2022.100187_bb0120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0130","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR endpoint study (CONFIDENCE)","author":"Green","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ahjo.2022.100187_bb0135","first-page":"1","article-title":"Initial drops in glomerular filtration rate with certain drug classes retard kidney disease progression","author":"Bakris","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ahjo.2022.100187_bb0140","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"164\u2013173","key":"10.1016\/j.ahjo.2022.100187_bb0145","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ahjo.2022.100187_bb0150","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.ajkd.2017.08.021","article-title":"Effects of intensive blood pressure treatment on acute kidney injury events in the systolic blood pressure intervention trial (SPRINT)","volume":"71","author":"Rocco","year":"2018","journal-title":"Am. J. Kidney Dis."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602222001045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602222001045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:28:23Z","timestamp":1763000903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602222001045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":30,"alternative-id":["S2666602222001045"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2022.100187","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolution of \u201cpillars of therapy\u201d to reduce heart failure risk and slow diabetic kidney disease progression","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2022.100187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100187"}}